LNAI
Lunai Bioworks Inc. Common Stock (LNAI)
Healthcare • NASDAQ • $0.48-30.14%
- Symbol
- LNAI
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.48
- Daily Change
- -30.14%
- Market Cap
- $3.08M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $13.28
- 52W Low
- $0.66
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- 0.35
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics platform, for multi-omics integration for target identification and validation; clinical trial optimization, including patient stratification and response monitoring; and screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics. The company was formerly known as Reno…
Company websiteResearch LNAI on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.